

Schedule 2 – Information on Management Positions

Martin Møller

Chairman of the Board since April 2022, member of the Board of Directors since 2021.

Education: MA in humanities from the University of Copenhagen.

Background: Worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner, until 2021. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.

Other ongoing assignments: Board member in Immunovia AB, Edvince AB, Rehler AS and Re-Zip ApS.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 6.266 shares and 128.542 warrants.

Jørgen Bardenfleth

Deputy chairman of the Board of Directors in Scandion Oncology A/S, and member of the Board of Directors since 2018.

Education: MSc in Engineering from the Technical University of Denmark (DTU) and an MBA from the University of California, Los Angeles.

Background: Professional board member since 2013, prior General Manager in high tech companies Microsoft, Intel and Hewlett-Packard 1989-2013. Board and steering committee work in Danish Science Parks, Innovationsfonden and Innovation Technology consortias.

Other ongoing assignments: Chairman Impero A/S, Bizbrains A/S, Dubex A/S og Symbion A/S, Vice Chairman at BLOXHUB, Board member at CN3 A/S, BIM Genetics Aps, Accelerace, Jumpstory Aps, Vallø Stift, Copenhagen Capacity.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 457.629 shares and 96.407 warrants (*partly owned via Lioneagle ApS*).

Alejandra Mørk

Member of the Board of Directors in Scandion Oncology A/S since April 2022.

Education: PhD and MSc Pharm.

Background: Worked all her career in drug development. First in Nycomed Pharma for 18 years in various leadership positions in Project Management, Clinical Development, Regulatory Affairs and as overall responsible for Drug Development being part of Nycomed top-management. In 2008 Alejandra acquired KLIFO A/S to build an international drug development consultancy supporting biotech and pharma companies to progress and increase value of their product development projects. Alejandra Mørk has since 2011 been member of the Board of Danish Biotech.

Other ongoing assignments: Board member in Danish Biotech. CEO of KLIFO A/S and member of the Danish Academy of Technical Sciences.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 64.271 warrants.

Keld Flintholm Jørgensen

Member of the Board of Directors in Scandion Oncology A/S since April 2022.

Education: BSc in Economics & Business Administration and MSc in Business Economics & Auditing, Copenhagen Business School.

Background: +20 years of experience within the global pharma industry across different functional areas such as Business Development, Corporate Strategy, Finance and Auditing. Served in several finance leadership positions at Roche from 2000 and until 2011, where he joined Roche Strategic Partnering. From 2017 he was promoted to Global Head of Roche Strategic Partnering and a member of the Roche Pharma's Late Stage Portfolio Committee. In 2019, Keld joined Lundbeck as EVP and Chief Business Officer, responsible for Corporate Strategy and Business Development. During the past +10 years in BD, Keld has executed M&A's and partnering deals worth >10 bio USD

Other ongoing assignments: EVP & Chief Business Officer of Lundbeck A/S.

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 64.271 warrants.

Martine J. van Vugt

Member of the Board of Directors since April 2022.

Education: PhD.

Background: +20 years of biotechnology industry experience and is a proven leader with a successful track record of leading high-performing, global cross-functional teams in a networked biotech environment. She is skilled in developing joint business value propositions, designing partnership structures and management of alliances. Martine is an expert in corporate transactional and licensing operations, including strategic partnering, in- and out-licensing as well as asset divestment and purchases. She is recognized internally and in industry for her strong leadership, communication and negotiation skills, and effectively blends analytical skills with a natural leadership style grounded in integrity and science. Martine is an inventor of Darzalex® and Tepezza.

Other ongoing assignments: Executive Vice President and Chief Strategy Officer at Genmab. Board member in Immagene B.V., NOXXON Pharma N.V and HollandBIO

Independence: Independent in relation to both the Company and executive management as well as larger shareholders.

Scandion Oncology shares and warrants: 64.271 warrants.